Loading...
Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
Gopie, F A Commiesie, E Baldi, S Kamst, M Kaur, D de Lange, W C M Pinas, P S Stijnberg, D Wongsokarijo, M Zijlmans, C W R
Gopie, F A
Commiesie, E
Baldi, S
Kamst, M
Kaur, D
de Lange, W C M
Pinas, P S
Stijnberg, D
Wongsokarijo, M
Zijlmans, C W R
Citations
Altmetric:
Series / Report no.
Open Access
Type
Article
Language
en
Date of publication
2021-01-29
Year of publication
Research Projects
Organizational Units
Journal Issue
Title
Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
Translated Title
Published in
J Clin Tubercul Other Mycobact Dis 2021; 23:100222
Abstract
We collected demographic and clinical characteristics and treatment outcome of TB patients from May 2012-December 2018 and performed a univariate and multivariate analysis to assess possible associations with resistance to rifampicin. Secondly, we conducted whole genome sequencing on all available Mycobacterium tuberculosis isolates that had a rifampicin resistance in the Xpert MTB/RIF test and performed phenotypic DST on selected isolates.